Balchem Co. (NASDAQ:BCPC) Shares Acquired by Raymond James & Associates

Raymond James & Associates increased its position in shares of Balchem Co. (NASDAQ:BCPC) by 7.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 54,089 shares of the basic materials company’s stock after acquiring an additional 3,741 shares during the quarter. Raymond James & Associates owned approximately 0.17% of Balchem worth $9,520,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Balchem by 3.8% in the first quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock valued at $609,873,000 after purchasing an additional 144,423 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Balchem by 32.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 193,146 shares of the basic materials company’s stock valued at $29,929,000 after buying an additional 47,036 shares during the period. Conestoga Capital Advisors LLC increased its stake in shares of Balchem by 2.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,155,209 shares of the basic materials company’s stock valued at $177,844,000 after acquiring an additional 29,825 shares during the last quarter. Watts Gwilliam & Co. LLC acquired a new position in shares of Balchem during the 3rd quarter valued at about $3,639,000. Finally, William Blair Investment Management LLC lifted its holdings in shares of Balchem by 8.4% during the 2nd quarter. William Blair Investment Management LLC now owns 233,831 shares of the basic materials company’s stock worth $35,998,000 after acquiring an additional 18,104 shares during the period. 87.91% of the stock is owned by hedge funds and other institutional investors.

Balchem Stock Down 0.9 %

BCPC opened at $169.26 on Wednesday. Balchem Co. has a 1 year low of $113.90 and a 1 year high of $186.03. The firm has a 50 day moving average price of $171.75 and a 200 day moving average price of $162.70. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The company has a market cap of $5.49 billion, a PE ratio of 47.81, a price-to-earnings-growth ratio of 5.43 and a beta of 0.65.

Analyst Ratings Changes

Several equities analysts recently commented on BCPC shares. HC Wainwright upped their price target on shares of Balchem from $170.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a report on Monday.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.